z-logo
open-access-imgOpen Access
Prognostic value of FoxP3 and CTLA-4 expression in patients with oral squamous cell carcinoma
Author(s) -
Kazushige Koike,
Hironari Dehari,
Kazuhiro Ogi,
Shota Sasaki,
Koyo Nishiyama,
Tomoko Sonoda,
Takanori Sasaki,
Takashi Sasaya,
Kei Tsuchihashi,
Tadashi Hasegawa,
Toshihiko Torigoe,
Hiroyoshi Hiratsuka,
Akira Miyazaki
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0237465
Subject(s) - foxp3 , parenchyma , stroma , pathology , medicine , regulatory t cell , immunohistochemistry , cancer research , immune system , t cell , il 2 receptor , immunology
Background Tumor-infiltrating lymphocytes include tumor-reactive lymphocytes and regulatory T-cells. However, the prognostic value of tumor-infiltrating lymphocytes in oral squamous cell carcinoma (OSCC) remains unclear. Methods We used immunohistochemistry to evaluate the presence of tumor-infiltrating FoxP3⁺ T-cells and CTLA-4⁺ cells in four distinct histological compartments (tumor parenchyma and stroma at the tumor center, and parenchyma and stroma at the invasive front) and assessed the association between the prevalence of these cells and the histopathological status of 137 patients with OSCC. Results Five-year overall survival, disease-specific survival, and recurrence-free survival were favorable in patients with high numbers of FoxP3⁺ T-cells in the parenchyma of the invasive front. Recurrence-free survival and metastasis-free survival were decreased in patients with high numbers of CTLA-4⁺ cells in the parenchyma of the invasive front. Conclusions The presence of FoxP3⁺ T-cells in the parenchyma of the invasive front may be a useful prognostic factor. Our results indicate that FoxP3⁺ T-cells may exert site-specific anti-tumor effects but may not play an immunosuppressive role in OSCC. In addition, our results suggest that CTLA-4 + cells suppress the function of FoxP3 + T-cells and promote anti‐tumor immunity in OSCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here